MYSTERIOUS: Tg rapeutics - What They Never Told You

5 Analysts Have This to Say About TG Therapeutics

Analysts have provided the following ratings for TG Therapeutics (NASDAQ:TGTX) within the last quarter:

Benzinga · Jun 13, 2022

Peering Into TG Therapeutics's Recent Short Interest

TG Therapeutics's (NASDAQ:TGTX) short percent of float has fallen 8.05% since its last report. The company recently reported that it has 19.37 million shares sold short, which is 14.63% of all regular shares that are available for trading.

Benzinga · May 20, 2022

12 Health Care Stocks Moving In Friday's Intraday Session

 

Benzinga · May 20, 2022

Why TG Therapeutics Stock Is Plunging Today

TG Therapeutics Inc (NASDAQ: TGTX) shares are trading significantly lower Monday morning after the company announced it has voluntarily withdrawn the pending Biologics License Application/supplemental New Drug Application for the combination of ublituximab and UKONIQ for the treatment of

Benzinga · Apr 18, 2022

Looking Into TG Therapeutics's Return On Capital Employed

TG Therapeutics (NASDAQ:TGTX) brought in sales totaling $2.32 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 8.99%, resulting in a loss of $93.34 million.

Benzinga · Mar 4, 2022